Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein

15 Jun 2012

Abstract excerpt

Persistent infection with high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer, one of most common cancer among woman worldwide, and represents an important risk factor associated with other anogenital and oropharyngeal cancers in men and women. Here, we designed a therapeutic vaccine based on integrase defective lentiviral vector (IDLV) to deliver a mutated nononcogenic form of HPV16...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Immunotherapy and Immune Responses
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22700466
DOI: 10.1002/ijc.27676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 proteinPMID 22700466Read ↗

Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope VaccineSemantic proximity Read ↗

Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6Semantic proximity Read ↗

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approachesSemantic proximity Read ↗

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated diseaseSemantic proximity Read ↗

DNA vaccines for cervical cancer: from bench to bedsideSemantic proximity Read ↗

Therapeutic vaccines against HPV16-associated tumors. Minireview.Semantic proximity Read ↗

Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 proteinSemantic proximity Read ↗

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.Semantic proximity Read ↗

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA VaccineSemantic proximity Read ↗

The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV)Semantic proximity Read ↗

EDA-E7 activated DCs induces specific cytotoxic T lymphocyte immune responses against HPV expressing cervical cancer in human settingSemantic proximity Read ↗

Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.